熱門資訊> 正文
EyePoint因与铅资产相关的索赔而受到关注
2026-03-21 22:23
- EyePoint (EYPT) has filed a lawsuit against Ocular Therapeutix (OCUL) in a Massachusetts federal court, alleging that its rival eye drug developer made false claims regarding its lead candidate, Duravyu.
- According to the lawsuit filed in Middlesex County Superior Court in Massachusetts on Friday, EyePoint (EYPT) accused Ocular (OCUL) of spreading false or misleading information regarding the company and clinical findings of Duravyu.
- The intravitreal injection is currently undergoing late-stage development for ophthalmic conditions, including wet age-related macular degeneration (wet AMD), a condition targeted by Ocular’s (OCUL) lead asset, Axpaxli. Both treatments belong to a class of drugs known as tyrosine kinase inhibitors.
- The lawsuit seeks an injunction to block the defendant from continuing with the alleged dissemination of false claims, retraction of the statements, and recovery of financial damages.
More on EyePoint Pharmaceuticals, Ocular Therapeutix
- EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check
- EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
- Ocular Therapeutix, Inc. (OCUL) Presents at 49th Annual Meeting of the Macula Society - Slideshow
- EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
- Ocular drops after late-stage trial data for wet AMD therapy
推薦文章
美股機會日報 | 特朗普再放豪言！正與伊朗談判，並收到伊方「大禮」；特斯拉機器人再迎新進展！馬斯克稱有望明年實現量產
一圖看懂 | 單季盈利承壓！拼多多Q4營收1239億元同比增12%，調后淨利卻下跌12%；高管稱「力爭三年再造一個拼多多」
財報前瞻 | 美團Q4財報將放榜！大摩、高盛逆勢力挺股價，當前美團已嚴重超跌？
中東戰火中金價狂瀉11%！創43年最慘周跌，避險邏輯崩塌還是黃金坑？
美股機會日報 | 中東硝煙將散？以官員稱美方4月9日結束對伊戰爭！海力士擬籌資百億赴美上市，豪擲80億美元鎖定阿斯麥光刻機！
一圖看懂 | 連續5個季度破千億！小米Q4營收1169億創歷史新高；淨利大增43.8%至63億元
無論美伊談判真假！華爾街已從特朗普引發的五分鍾狂飆獲得明確信號？
麥格理：緊張局勢緩和后布倫特原油底部在每桶85至90美元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
